Fujimura M, Sakamoto S, Nishi K, Saito M, Miyake Y, Matsuda T
Third Department of Internal Medicine, Kanazawa University School of Medicine, Japan.
Clin Exp Allergy. 1991 Mar;21(2):189-94. doi: 10.1111/j.1365-2222.1991.tb00829.x.
This study was designed to examine whether an inhaled beta 2-agonist, procaterol, inhibits thromboxane A2 (TXA2) production induced by antigen challenge in passively sensitized guinea-pigs in vivo. Antigen-induced bronchoconstriction was markedly inhibited by pre-treatment with procaterol. Inhaled procaterol significantly reduced in a dose-dependent manner the increment in TXB2 concentration in bronchoalveolar lavage fluid obtained 5 min after antigen challenge. Aerosol administration of procaterol significantly inhibited bronchoconstriction induced by inhaled histamine. These results suggest that inhalation of procaterol has an inhibitory effect on antigen-induced TXA2 production as well as a protective effect against bronchoconstriction induced by bronchoactive agents.
本研究旨在探讨吸入性β2受体激动剂丙卡特罗是否能抑制被动致敏豚鼠体内抗原激发诱导的血栓素A2（TXA2）生成。预先用丙卡特罗治疗可显著抑制抗原诱导的支气管收缩。吸入丙卡特罗以剂量依赖方式显著降低抗原激发后5分钟获得的支气管肺泡灌洗液中TXB2浓度的升高。丙卡特罗气雾剂给药可显著抑制吸入组胺诱导的支气管收缩。这些结果表明，吸入丙卡特罗对抗原诱导的TXA2生成具有抑制作用，同时对支气管活性剂诱导的支气管收缩具有保护作用。
